Study Region Study design Sex Sex Age (yrs) Treatment Study Duration (mo) Proteinuria* Remission
Male Female
Dahan 2016
France
RCT
T: 28 C: 24 T: 9 C: 14 T: 53.0 (42.0-63.0) C: 58.5 (43.0-64.0) T: NIAT+RTX C: NIAT
23
T: 7680.0 (4584.3-10399.0) C: 7195.1 (5363.1-8965.1) T: 24 C: 13
Seitz-Polski 2017
France
RCT
T: 23 C: 19 T: 6 C: 10 T: 52.0 (41.0-63.0) C: 59.0 (44.0-63.0) T: RTX C: NIAT
23
T: 7.4 (6.2-9.0) C: 8.4 (4.4-11.0) T: 19 C: 13
Rosenzwajg 2017
France
RCT
T: 16 C: 9 T: 16 C: 9 T: 57.0 (26.0-74.0) C: 57.0 (26.0-74.0) T: NIAT+RTC C: NIAT
6
T: 7590 (3440.0-11000.0) C: 6250 (3170.0-15900.0) T: 9 C: 5
van den Brand 2017
Italy
Prospective cohort study
T: 72 C: 76 T: 28 C: 27 T: 51.5±15.9 C: 55.3±12.7 T: RTX C: steroid+ cyclical CYC
40
T: 6400 (4400.0-8894.0) C: 8840 (5651.0-11660.0) T: 90 C: 123
Fervenza 2019
Canada
RCT
T: 47 C: 53 T: 18 C: 12 T: 51.9±12.6 C: 52.2±12.4 T: RTX C: CYC
24
T: 8.9 (6.8-12.3) C: 8.9 (6.7-12.9) T: 39 C: 13
Fenoglio (SD) 2020
Italy
Retrospective case-control study
T: 9 C: 8 T: 6 C: 6 T: 61.4±11.5 C: 67.1±17.5 T: RTX C: Ponticelli Protocol*
24
T: 5.1±1.4 C: 8.3±4.8 T: 13 C: 12